GlassScriptPhysician profile
Ahmad Tarek Chami
NPI 1730506866
$4,930.22
in general payments reported to CMS, 2019-2025
34 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $637 · 2021: $1,343 · 2022: $632 · 2023: $1,205 · 2024: $296 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840 · Travel and Lodging: $598 · Education: $220 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.92 |
| Travel and Lodging | $598.14 |
| Education | $220.20 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $748.14 | 2023 | |
| Cardiovascular Systems INC. | $412.76 | 2021-2022 | |
| Medtronic Vascular, INC. | $400.15 | 2019-2020 | |
| Medtronic, INC. | $395.81 | 2021-2023 | Linq II |
| Astrazeneca Pharmaceuticals LP | $336.67 | 2019-2025 | Brilinta, Farxiga |
| Edwards Lifesciences Corporation | $287.53 | 2021 | |
| Pfizer INC. | $237.01 | 2019-2023 | |
| Abbott Laboratories | $228.64 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.68 | 2020-2025 | Lifevest |
| Amgen INC. | $175.16 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $168.51 | 2019-2024 | Xarelto |
| Abiomed | $149.34 | 2022 | |
| Chiesi USA, INC. | $132.02 | 2021 | |
| Cvrx, INC. | $122.44 | 2022-2025 | Barostim Neo System |
| Kerecis Limited | $120.78 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $99.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.51 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $78.29 | 2019-2025 | |
| Genzyme Corporation | $60.67 | 2019 | |
| United Therapeutics Corporation | $57.77 | 2024-2025 | Tyvaso, Tyvaso |
| Alnylam Pharmaceuticals INC. | $48.29 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $43.17 | 2024 | |
| Sanofi-Aventis U.S. LLC | $40.10 | 2020-2021 | |
| Esperion Therapeutics, INC. | $37.17 | 2021-2024 | Nexletol |
| Straumann USA LLC | $34.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.30 | 2021-2023 | Eliquis |
| Baxter Healthcare | $30.39 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Portola Pharmaceuticals, LLC | $28.81 | 2019 | |
| Merck Sharp & Dohme LLC | $27.43 | 2022-2023 | Verquvo |
| Alexion Pharmaceuticals, INC. | $23.68 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $23.33 | 2024 | Arcalyst |
| Terumo Medical Corporation | $22.96 | 2022 | |
| Getinge USA Sales, LLC | $21.22 | 2021 | |
| Lantheus Medical Imaging, INC. | $16.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Tarek Chami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.